Lavaca Capital LLC Grows Position in Bristol-Myers Squibb (NYSE:BMY)

Lavaca Capital LLC grew its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,395 shares of the biopharmaceutical company’s stock after buying an additional 295 shares during the quarter. Lavaca Capital LLC’s holdings in Bristol-Myers Squibb were worth $238,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Northwest Financial Advisors purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $27,000. ESL Trust Services LLC bought a new position in shares of Bristol-Myers Squibb in the first quarter worth approximately $27,000. Accordant Advisory Group Inc purchased a new stake in shares of Bristol-Myers Squibb in the first quarter worth $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $34,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $40,000. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald reiterated a “neutral” rating and issued a $45.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. BMO Capital Markets cut their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. Finally, Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $55.79.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY traded down $1.48 on Monday, reaching $48.97. The company’s stock had a trading volume of 22,276,796 shares, compared to its average volume of 15,962,543. The company has a 50-day simple moving average of $41.87 and a 200 day simple moving average of $46.75. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The company has a market cap of $99.27 billion, a P/E ratio of -15.80, a PEG ratio of 17.25 and a beta of 0.44. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.41.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 11.52% and a negative net margin of 14.06%. The company had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter last year, the business posted $1.75 earnings per share. The firm’s revenue was up 8.7% on a year-over-year basis. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.90%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.